{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:52:39Z","timestamp":1793332359454,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40264-022-01157-4","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T07:03:01Z","timestamp":1652770981000},"page":"429-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["\u201cArtificial Intelligence\u201d for Pharmacovigilance: Ready for Prime Time?"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1609-7420","authenticated-orcid":false,"given":"Robert","family":"Ball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Dal Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"1157_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/cpt.1771","volume":"107","author":"Q Liu","year":"2020","unstructured":"Liu Q, Zhu H, Liu C, et al. Application of machine learning in drug development and regulation: current status and future potential. Clin Pharmacol Ther. 2020;107:726\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1157_CR2","unstructured":"US FDA. Guidance for industry\u2014good pharmacovigilance practices and pharmacoepidemiologic assessment. 2005. https:\/\/www.fda.gov\/media\/71546\/download. Accessed 30 Nov 2021."},{"key":"1157_CR3","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMp1809643","volume":"379","author":"R Platt","year":"2018","unstructured":"Platt R, Brown JS, Robb M, McClellan M, Ball R, Nguyen M, et al. The FDA sentinel initiative\u2014an evolving national resource. N Engl J Med. 2018;379:2091\u20133.","journal-title":"N Engl J Med"},{"key":"1157_CR4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/pds.4645","volume":"27","author":"R Ball","year":"2018","unstructured":"Ball R, Toh S, Nolan J, Haynes K, Forshee R, Botsis T. Evaluating automated approaches to anaphylaxis case classification using unstructured data from the FDA Sentinel System. Pharmacoepidemiol Drug Saf. 2018;27:1077\u201384.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1157_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jamia\/ocaa028","volume":"27","author":"JS Brown","year":"2020","unstructured":"Brown JS, Maro JC, Nguyen MD, Ball R. Using and improving distributed data networks to generate actionable evidence: The case of real-world outcomes in the Food and Drug Administration\u2019s Sentinel System. J Am Med Inform Assoc. 2020;27:793\u20137.","journal-title":"J Am Med Inform Assoc"},{"key":"1157_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/jamia\/ocab036","volume":"28","author":"TB Gibson","year":"2021","unstructured":"Gibson TB, Nguyen M, Burrell T, Yoon F, Wong J, Dharmarajan S, et al. Electronic phenotyping of health outcomes of interest using a linked claims-electronic health record database: findings from a machine learning pilot project. J Am Med Inform Assoc. 2021;28:1507\u201317.","journal-title":"J Am Med Inform Assoc"},{"key":"1157_CR7","unstructured":"Ball R. Artificial Intelligence in the FDA\u2019s Sentinel System. In: Anklamm E, Bahlb MI, Ball R, et al. Emerging technologies and their application to regulatory science. Experimental biology and medicine. 2021;246:15\u201318."},{"key":"1157_CR8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/cpt.944","volume":"104","author":"E Pinnow","year":"2018","unstructured":"Pinnow E, Amr S, Bentzen SM, et al. Postmarket safety outcomes for new molecular entity (NME) drugs approved by the Food and Drug Administration between 2002 and 2014. Clin Pharmacol Ther. 2018;104:390\u2013400.","journal-title":"Clin Pharmacol Ther"},{"key":"1157_CR9","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/cpt.1948","volume":"108","author":"I Bulatao","year":"2020","unstructured":"Bulatao I, Pinnow E, Day B, Cherkaoui S, Kalaria M, Brajovic S, et al. Postmarketing safety-related regulatory actions for new therapeutic biologics approved in the United States 2002\u20132014: similarities and differences with new molecular entities. Clin Pharmacol Ther. 2020;108:1243\u201353.","journal-title":"Clin Pharmacol Ther"},{"key":"1157_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/pds.3395","volume":"22","author":"J Lester","year":"2013","unstructured":"Lester J, Neyarapally GA, Lipowski E, Graham CF, Hall M, Dal Pan G. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf. 2013;22:302\u20135.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1157_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/pds.3423","volume":"22","author":"M Kulldorff","year":"2013","unstructured":"Kulldorff M, Dashevsky I, Avery TR, Chan KA, Davis RL, Graham D, et al. Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol Drug Saf. 2013;22:517\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1157_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2042098619864744","volume":"10","author":"A Bate","year":"2019","unstructured":"Bate A, Hornbuckle K, Juhaeri J, Motsko SP, Reynolds RF. Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance. Ther Adv Drug Saf. 2019;10:1\u20139.","journal-title":"Ther Adv Drug Saf."},{"key":"1157_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14740338.2017.1325463","volume":"16","author":"M Arnaud","year":"2017","unstructured":"Arnaud M, B\u00e9gaud B, Thurin N, Moore N, Pariente A, Salvo F. Methods for safety signal detection in healthcare databases: a literature review. Expert Opin Drug Saf. 2017;16:721\u201332.","journal-title":"Expert Opin Drug Saf"},{"key":"1157_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jbi.2017.10.013","volume":"76","author":"R Harpaz","year":"2017","unstructured":"Harpaz R, DuMouchel W, Schuemie M, et al. Toward multimodal signal detection of adverse drug reactions. J Biomed Informat. 2017;76:41\u20139.","journal-title":"J Biomed Informat."},{"key":"1157_CR15","doi-asserted-by":"crossref","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, E2D(R1), Final Concept Paper for E2D(R1). 2021. https:\/\/database.ich.org\/sites\/default\/files\/E2D-R1_ConceptPaper_Final_2020_0115.pdf. Accessed 30 Nov 2021.","DOI":"10.1093\/hmg\/ddab030"},{"key":"1157_CR16","unstructured":"US FDA. Artificial Intelligence and Machine Learning (AI\/ML) Software as a Medical Device Action Plan. 2021. https:\/\/www.fda.gov\/medical-devices\/software-medical-device-samd\/artificial-intelligence-and-machine-learning-software-medical-device. Accessed 30 Nov 2021."},{"key":"1157_CR17","unstructured":"McCarthy J. What Is Artificial Intelligence? Stanford, CA: Stanford University. 2007. http:\/\/jmc.stanford.edu\/articles\/whatisai\/whatisai.pdf. Accessed 30 Nov 2021."},{"key":"1157_CR18","unstructured":"\u201cDefinition of natural language processing\u201d. Oxford University Press. Lexico.com. 2021. https:\/\/www.lexico.com\/definition\/natural_language_processing. Accessed 30 Nov 2021."},{"key":"1157_CR19","unstructured":"Electronic Code of Federal Regulations. Title 21: Food and Drugs Part 314.80 (f). 2021. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=314.80. Accessed 30 Nov 2021."},{"key":"1157_CR20","unstructured":"Electronic Code of Federal Regulations. Title 21: Food and Drugs Part 314.80 (b). 2021. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=314.80. Accessed 30 Nov 2021."},{"key":"1157_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/cpt.1255","volume":"105","author":"J Schmider","year":"2019","unstructured":"Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel PM. Innovation in pharmacovigilance: use of artificial intelligence in adverse event case processing. Clin Pharmacol Ther. 2019;105:954\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"1157_CR22","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, E2D(R1). 2021. https:\/\/database.ich.org\/sites\/default\/files\/E2D_Guideline.pdf. Accessed 30 Nov 2021."},{"key":"1157_CR23","unstructured":"Electronic Code of Federal Regulations. Title 21: Food and Drugs Part 314.80. 2021. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=314.80. Accessed 30 Nov 2021."},{"key":"1157_CR24","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, E2B(R3) clinical safety data management: data elements for transmission of individual case safety reports. 2021. https:\/\/ich.org\/page\/e2br3-individual-case-safety-report-icsr-specification-and-related-files. Accessed 30 Nov 2021."},{"key":"1157_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","volume":"31","author":"B Taofikat","year":"2008","unstructured":"Taofikat B, Agbabiaka JS, Edzard E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31:21\u201337.","journal-title":"Drug Saf"},{"key":"1157_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40264-017-0509-2","volume":"40","author":"R Edwards","year":"2017","unstructured":"Edwards R. Causality assessment in pharmacovigilance: still a challenge. Drug Saf. 2017;40:365\u201372.","journal-title":"Drug Saf"},{"key":"1157_CR27","unstructured":"US FDA. Best practices in drug and biological product postmarket safety surveillance for FDA Staff, MAPP 4121.3. 2021. https:\/\/www.fda.gov\/media\/130216\/download. Accessed 30 Nov 2021."},{"key":"1157_CR28","unstructured":"US FDA. Collaborative identification, evaluation, and resolution of a newly identified safety signal (NISS). 2021. https:\/\/www.fda.gov\/media\/137475\/download. Accessed 30 Nov 2021."},{"key":"1157_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104517","volume":"135","author":"K Kreimeyer","year":"2021","unstructured":"Kreimeyer K, Dang O, Spiker J, Mu\u00f1oz M, Rosner G, Ball R, et al. Feature engineering and machine learning for causality assessment in pharmacovigilance: lessons learned from application to the FDA adverse event reporting system (FAERS). Comput Biol Med. 2021;135: 104517. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104517.","journal-title":"Comput Biol Med"},{"key":"1157_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1631\/FITEE.1700053","volume":"18","author":"N Zheng","year":"2017","unstructured":"Zheng N, Liu Z, Ren P, Ma Y, Chen S, Yu S, et al. Hybrid-augmented intelligence: collaboration and cognition. Front Inform Technol Electron Eng. 2017;18:153\u201379.","journal-title":"Front Inform Technol Electron Eng"},{"key":"1157_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40264-020-01030-2","volume":"44","author":"K Huysentruyt","year":"2021","unstructured":"Huysentruyt K, Kjoersvik O, Dobracki P, Savage E, Mishalov E, Cherry M, et al. Validating intelligent automation systems in pharmacovigilance: insights from good manufacturing practices. Drug Saf. 2021;44:261\u201372.","journal-title":"Drug Saf"},{"key":"1157_CR32","first-page":"7","volume":"34","author":"R Ghosh","year":"2020","unstructured":"Ghosh R, Kempf D, Pufko A, Barrios Martinez LF, Davis CM, et al. Automation opportunities in pharmacovigilance: an industry survey. Pharmaceut Med. 2020;34:7\u201318.","journal-title":"Pharmaceut Med."},{"key":"1157_CR33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s43441-019-00023-3","volume":"54","author":"DJ Lewis","year":"2020","unstructured":"Lewis DJ, McCallum JF. Utilizing advanced technologies to augment pharmacovigilance systems: challenges and opportunities. Ther Inn Reg Sci. 2020;54:888\u201399.","journal-title":"Ther Inn Reg Sci"},{"key":"1157_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40264-019-00869-4","volume":"43","author":"R Routray","year":"2020","unstructured":"Routray R, Tetarenko N, Abu-Assal C, et al. Application of augmented intelligence for pharmacovigilance case seriousness determination. Drug Saf. 2020;43:57\u201366.","journal-title":"Drug Saf"},{"key":"1157_CR35","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s40264-018-0690-y","volume":"41","author":"S Comfort","year":"2018","unstructured":"Comfort S, Dorrell D, Meireis S, Fine J. MOdified NARanjo causality scale for ICSRs (MONARCSi): a decision support tool for safety scientists. Drug Saf. 2018;41:1073\u201385.","journal-title":"Drug Saf"},{"key":"1157_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/amiajnl-2010-000022","volume":"18","author":"T Botsis","year":"2011","unstructured":"Botsis T, Nguyen MD, Ball R, et al. Text mining for the Vaccine Adverse Event Reporting System: medical text classification using informative feature selection. J Am Med Inform Assoc. 2011;18:631\u20138.","journal-title":"J Am Med Inform Assoc"},{"key":"1157_CR37","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/amiajnl-2012-000881","volume":"19","author":"T Botsis","year":"2012","unstructured":"Botsis T, Nguyen MD, Woo EJ, Buttolph T, Winiecki S, Ball R. Vaccine Adverse Event Text Mining (VaeTM) system for extracting features from vaccine safety reports. J Am Med Inform Assoc. 2012;19:1011\u20138.","journal-title":"J Am Med Inform Assoc"},{"key":"1157_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4338\/ACI-2013-04-RA-0028","volume":"4","author":"T Botsis","year":"2013","unstructured":"Botsis T, Ball R. Automating case definitions using literature-based reasoning. Appl Clin Inform. 2013;4:515\u201327.","journal-title":"Appl Clin Inform"},{"key":"1157_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4338\/ACI-2012-11-RA-0049","volume":"4","author":"T Botsis","year":"2013","unstructured":"Botsis T, Woo EJ, Ball R. The contribution of the vaccine adverse event text mining system to the classification of possible Guillain-Barre syndrome reports. Appl Clin Inform. 2013;4:88\u201399.","journal-title":"Appl Clin Inform"},{"key":"1157_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40264-013-0064-4","volume":"36","author":"T Botsis","year":"2013","unstructured":"Botsis T, Woo EJ, Ball R. Application of information retrieval approaches to case classification in the vaccine adverse event reporting system. Drug Saf. 2013;36:573\u201382.","journal-title":"Drug Saf"},{"key":"1157_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/clpt.2011.119","volume":"90","author":"R Ball","year":"2011","unstructured":"Ball R, Botsis T. Can network analysis improve pattern recognition among adverse events following immunization reported to VAERS? Clin Pharmacol Ther. 2011;90:271\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1157_CR42","first-page":"564","volume":"169","author":"T Botsis","year":"2011","unstructured":"Botsis T, Ball R. Network analysis of possible anaphylaxis cases reported to the US Vaccine Adverse Event Reporting System after H1N1 influenza vaccine. Stud Health Technol Inform. 2011;169:564\u20138.","journal-title":"Stud Health Technol Inform."},{"key":"1157_CR43","first-page":"1178","volume":"205","author":"T Botsis","year":"2014","unstructured":"Botsis T, Scott J, Goud R, Toman P, Sutherland A, Ball R. Novel algorithms for improved pattern recognition using the US FDA adverse event network analyzer. Stud Health Technol Inform. 2014;205:1178\u201382.","journal-title":"Stud Health Technol Inform."},{"key":"1157_CR44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/sam.11233","volume":"7","author":"M Markatou","year":"2014","unstructured":"Markatou M, Ball R. A pattern discovery framework for adverse event evaluation and inference in spontaneous reporting systems. Stat Anal Dat Min. 2014;7:352\u201367.","journal-title":"Stat Anal Dat Min."},{"key":"1157_CR45","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1109\/JBHI.2014.2345873","volume":"19","author":"T Botsis","year":"2015","unstructured":"Botsis T, Scott J, Woo EJ, Ball R. Identifying similar cases in document networks using cross-reference structures. IEEE J Biomed Health Inform. 2015;19:1906\u201317.","journal-title":"IEEE J Biomed Health Inform"},{"key":"1157_CR46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jbi.2016.06.006","volume":"62","author":"W Wang","year":"2016","unstructured":"Wang W, Kreimeyer K, Woo EJ, Ball R, Foster M, Pandey A, et al. A new algorithmic approach for the extraction of temporal associations from clinical narratives with an application to medical product safety surveillance reports. J Biomed Inform. 2016;62:78\u201389.","journal-title":"J Biomed Inform"},{"key":"1157_CR47","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1145\/3019612.3022875","volume":"2017","author":"S Wunnava","year":"2017","unstructured":"Wunnava S, Qin X, Rundensteiner EA, et al. Towards transforming FDA adverse event narratives into actionable structured data for improved pharmacovigilance. Proc Symp Appl Comput (SAC). 2017;2017:777\u201382.","journal-title":"Proc Symp Appl Comput (SAC)"},{"key":"1157_CR48","doi-asserted-by":"crossref","unstructured":"Wunnava S, Qin X, Kakar T, Kong X, Rundensteiner EA, Sahoo SK, et al. One Size does not fit all: an ensemble approach towards information extraction from adverse drug event narratives. In: Proceedings of the 11th international joint conference on biomedical engineering systems and technologies\u2014volume 5: HEALTHINF; 2018. pp. 176\u2013188.","DOI":"10.5220\/0006600201760188"},{"key":"1157_CR49","doi-asserted-by":"publisher","first-page":"396","DOI":"10.4338\/ACI-2016-10-RA-0169","volume":"8","author":"T Botsis","year":"2017","unstructured":"Botsis T, Foster M, Arya N, Kreimeyer K, Pandey A, Arya D. Application of natural language processing and network analysis techniques to post-market reports for the evaluation of dose-related anti-thymocyte globulin safety patterns. App Clin Inform. 2017;8:396\u2013411.","journal-title":"App Clin Inform."},{"key":"1157_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jbi.2017.07.012","volume":"73","author":"K Kreimeyer","year":"2017","unstructured":"Kreimeyer K, Foster M, Pandey A, Arya N, Halford G, Jones SF, et al. Natural language processing systems for capturing and standardizing unstructured clinical information: a systematic review. J Biomed Inform. 2017;73:14\u201329.","journal-title":"J Biomed Inform"},{"key":"1157_CR51","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3414\/ME14-01-0066","volume":"55","author":"B Baer","year":"2016","unstructured":"Baer B, Nguyen M, Woo EJ, Winiecki S, Scott J, Martin D, et al. Can natural language processing improve the efficiency of vaccine adverse event report review? Meth Inform Med. 2016;55:144\u201350.","journal-title":"Meth Inform Med."},{"key":"1157_CR52","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jbi.2016.07.023","volume":"64","author":"T Botsis","year":"2016","unstructured":"Botsis T, Jankosky C, Arya D, et al. Decision support environment for medical product safety surveillance. J Biomed Inform. 2016;64:354\u201362.","journal-title":"J Biomed Inform"},{"key":"1157_CR53","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40264-017-0523-4","volume":"40","author":"K Kreimeyer","year":"2017","unstructured":"Kreimeyer K, Menschik D, Winiecki S, et al. Using probabilistic record linkage of structured and unstructured data to identify duplicate cases in spontaneous adverse event reporting systems. Drug Saf. 2017;40:571\u201382.","journal-title":"Drug Saf"},{"key":"1157_CR54","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/jamia\/ocx022","volume":"24","author":"L Han","year":"2017","unstructured":"Han L, Ball R, Pamer CA, et al. Development of an automated assessment tool for MedWatch reports in the FDA adverse event reporting system. J Am Med Inform Assoc. 2017;24:913\u201320.","journal-title":"J Am Med Inform Assoc"},{"key":"1157_CR55","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40264-019-00897-0","volume":"43","author":"MA Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz MA, Dal Pan GJ, Wei YJ, et al. Towards automating adverse event review: a prediction model for case report utility. Drug Saf. 2020;43:329\u201338.","journal-title":"Drug Saf"},{"key":"1157_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jbi.2018.05.019","volume":"83","author":"T Ly","year":"2018","unstructured":"Ly T, Pamer C, Dang O, Brajovic S, et al. Evaluation of natural language processing (NLP) systems to annotate drug product labeling with MedDRA terminology. J Biomed Inform. 2018;83:73\u201386.","journal-title":"J Biomed Inform"},{"key":"1157_CR57","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1177\/1460458217749883","volume":"25","author":"A Pandey","year":"2019","unstructured":"Pandey A, Kreimeyer K, Foster M, Botsis T, Dang O, Ly T, et al. Adverse event extraction from structured product labels using the event-based textmining of health electronic records (ETHER) system. Health Inform J. 2019;25:1232\u201343.","journal-title":"Health Inform J"},{"key":"1157_CR58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40264-020-00996-3","volume":"44","author":"S Bayer","year":"2021","unstructured":"Bayer S, Clark C, Dang O, et al. ADE Eval: an evaluation of text processing systems for adverse event extraction from drug labels for pharmacovigilance. Drug Saf. 2021;44:83\u201394.","journal-title":"Drug Saf"},{"key":"1157_CR59","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40264-020-00945-0","volume":"43","author":"J Spiker","year":"2020","unstructured":"Spiker J, Kreimeyer K, Dang O, Boxwell D, Chan V, Cheng C, et al. Information visualization platform for post-market surveillance decision support. Drug Saf. 2020;43:905\u201315.","journal-title":"Drug Saf"},{"key":"1157_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/frai.2021.659622","volume":"4","author":"X Wang","year":"2021","unstructured":"Wang X, Xu X, Tong W, Roberts R, Liu Z. InferBERT: a transformer-based causal inference framework for enhancing pharmacovigilance. Front Artif Intell. 2021;4: 659622. https:\/\/doi.org\/10.3389\/frai.2021.659622.","journal-title":"Front Artif Intell."},{"issue":"11","key":"1157_CR61","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1016\/j.drudis.2021.06.009","volume":"26","author":"Z Liu","year":"2021","unstructured":"Liu Z, Roberts RA, Lal-Nag M, et al. AI-based language models powering drug discovery and development. Drug Discovery Today. 2021;26(11):2593\u2013607.","journal-title":"Drug Discovery Today"},{"key":"1157_CR62","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/sim.8447","volume":"39","author":"Y Ding","year":"2020","unstructured":"Ding Y, Markatou M, Ball R. An evaluation of statistical approaches to post marketing surveillance. Stat Med. 2020;39:845\u201374.","journal-title":"Stat Med"},{"issue":"Suppl 3","key":"1157_CR63","doi-asserted-by":"publisher","first-page":"i68","DOI":"10.1136\/qshc.2010.042085","volume":"19","author":"DF Sittig","year":"2010","unstructured":"Sittig DF, Singh H. A new sociotechnical model for studying health information technology in complex adaptive healthcare systems. Qual Saf Health Care. 2010;19(Suppl 3):i68\u201374.","journal-title":"Qual Saf Health Care"},{"key":"1157_CR64","unstructured":"Mindell DA. Our robots, ourselves: robotics and the myths of autonomy. New York NY: Viking; 2015. ISBN: 978-0-525-42697-4."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01157-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:07:22Z","timestamp":1744700842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01157-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01157-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"10 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The views expressed are those of the authors and not necessarily those of the US FDA.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was conducted by employees of the US FDA as part of their official duties.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Robert Ball is an author on US Patent 9,075,796, \u2018Text mining for large medical text datasets and corresponding medical text classification using informative feature selection\u2019. At present, this patent is not licensed and does not generate royalties. Gerald Dal Pan has no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"RB conceived the manuscript structure, wrote the first draft, and made subsequent revisions. GDP contributed to the manuscript structure and revised multiple versions. Both authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}